01 2AVELUMAB
02 2CETRORELIX ACETATE
03 2CHORIOGONADOTROPIN ALFA
04 1CLADRIBINE
05 1CLOMIPHENE CITRATE
06 12FOLLITROPIN ALFA/BETA
07 23LEVOTHYROXINE SODIUM
08 7METFORMIN HYDROCHLORIDE
09 3MITOXANTRONE HYDROCHLORIDE
10 3SERMORELIN ACETATE
11 9SOMATROPIN
12 4SOMATROPIN RECOMBINANT
13 1TEPOTINIB HYDROCHLORIDE
01 20INJECTABLE;INJECTION
02 1INJECTABLE;INTRAVENOUS
03 14INJECTABLE;SUBCUTANEOUS
04 2POWDER;SUBCUTANEOUS
05 2TABLET, EXTENDED RELEASE;ORAL
06 31TABLET;ORAL
01 10.025MG
02 10.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
03 10.05MG
04 10.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
05 10.075MG
06 10.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
07 10.088MG
08 10.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
09 10.112MG
10 10.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
11 10.125MG
12 10.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
13 10.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
14 10.15MG
15 10.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
16 10.175MG
17 10.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
18 10.1MG
19 10.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
20 10.25MG/VIAL
21 10.2MG
22 10.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
23 20.3MG
24 11,050 IU/VIAL
25 110MG
26 1150 IU/0.25ML
27 2150 IU/VIAL
28 11GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
29 220MG/ML
30 1300 IU/0.5ML
31 237.5 IU/VIAL
32 1450 IU/0.75ML
33 1450 IU/VIAL
34 34MG/VIAL
35 2500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
36 150MG
37 35MG/VIAL
38 1625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
39 16MG/0.5ML (6MG/0.5ML)
40 36MG/VIAL
41 275 IU/VIAL
42 2750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
43 38.8MG/VIAL
44 1850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
45 1900 IU/1.5ML
46 1EQ 0.05MG BASE/AMP **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
47 1EQ 0.25MG /0.5ML
48 1EQ 0.25MG BASE/VIAL
49 1EQ 0.5MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
50 1EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
51 1EQ 20MG BASE/10ML (EQ 2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
52 1EQ 225MG BASE
53 1EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
54 1EQ 30MG BASE/15ML (EQ 2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
55 1EQ 3MG BASE/VIAL
01 27DISCN
02 14RX
03 29Blank
RLD :
TE Code :
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : BAVENCIO
Dosage Strength : 20MG/ML
Approval Date :
Application Number : 761049
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Dosage Form : INJECTABLE; INTRAVENOUS
Proprietary Name : BAVENCIO
Dosage Strength : 20MG/ML
Approval Date :
Application Number : 761078
RX/OTC/DISCN :
RLD :
TE Code :
RLD : Yes
TE Code : AP
Dosage Form : POWDER; SUBCUTANEOUS
Proprietary Name : CETROTIDE
Dosage Strength : EQ 0.25MG BASE/VIAL
Approval Date : 2000-08-11
Application Number : 21197
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AP
RLD : Yes
TE Code :
Dosage Form : POWDER; SUBCUTANEOUS
Proprietary Name : CETROTIDE
Dosage Strength : EQ 3MG BASE/VIAL
Approval Date : 2000-08-11
Application Number : 21197
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD :
TE Code :
Dosage Form : INJECTABLE; INJECTION
Proprietary Name : OVIDREL
Dosage Strength : 0.25MG/VIAL
Approval Date :
Application Number : 21149
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Dosage Form : INJECTABLE; SUBCUTANEOUS
Proprietary Name : OVIDREL
Dosage Strength : EQ 0.25MG /0.5ML
Approval Date :
Application Number : 21149
RX/OTC/DISCN :
RLD :
TE Code :
RLD : Yes
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : MAVENCLAD
Dosage Strength : 10MG
Approval Date : 2019-03-29
Application Number : 22561
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : No
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : SEROPHENE
Dosage Strength : 50MG
Approval Date : 1982-03-22
Application Number : 18361
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD :
TE Code :
Dosage Form : INJECTABLE; SUBCUTANEOUS
Proprietary Name : GONAL-F
Dosage Strength : 37.5 IU/VIAL
Approval Date :
Application Number : 21765
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Dosage Form : INJECTABLE; SUBCUTANEOUS
Proprietary Name : GONAL-F RFF
Dosage Strength : 75 IU/VIAL
Approval Date :
Application Number : 21765
RX/OTC/DISCN :
RLD :
TE Code :
